Research Synthesis: Senescence Cancer Effects

Research Synthesis: Senescence Cancer Effects

Abstract

This paper synthesizes evidence on senescence cancer effects across 13 accepted source papers and 220 high-confidence extracted claims.

The evidence profile contains no sources classified primarily as direct clinical evidence, 13 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 0 cross-study disagreements across the evidence base.

No single positive outcome class dominates the retained corpus; null signals cluster in the contextual adjacent evidence, muscle function, immune and inflammation outcome classes, and negative signals cluster in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that senescence cancer effects remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.

Methods

Review type and protocol

This manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-senescence_cancer_effects-v06-DAILY-2026-06-16T11-52-36Z.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-16.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

• senescence cancer effects aging
• senescence cancer effects older adults
• senescence cancer effects randomized controlled trial
• senescence aging
• senescence older adults
• senescence randomized controlled trial
• cancer aging
• cancer older adults
• cancer randomized controlled trial

Eligibility criteria

• Sources whose primary content addresses senescence cancer effects.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 761 records in the receipt-candidate union, 288 were classified as source candidates and 13 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

source admission funnel

Admission bucket	n
Receipt candidate union	761
Classified source candidates	288
No extractable claims	137
None-only claim binding	45
Mixed partial-or-none claim-binding candidates	208
Partial-only claim-binding candidates	63
Strict high-confidence sources	20
Admitted final sources	13

Exclusion reasons

• No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.

Risk-of-bias appraisal

Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses).

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (contextual adjacent evidence, frailty, immune and inflammation, longevity, muscle function); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. Certification under the researka_agent_certified model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

Results

Outcome-class note: Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

Evidence domain	Corpus slice	Strongest signal	Directness	Main limitation
Contextual Adjacent Evidence	n=8; claims=156	no extracted directional signal in 7/8 sources	7 indirect; 1 review	limited corpus depth in this outcome class
Longevity	n=2; claims=2	unclear signal in 1/2 sources	1 indirect; 1 review	limited corpus depth in this outcome class
Frailty	n=1; claims=5	no extracted directional signal in 1/1 sources	1 review	single-source slice; hypothesis-generating
Immune and Inflammation	n=1; claims=10	no extracted directional signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating
Muscle Function	n=1; claims=47	no extracted directional signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating

This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.

Contextual Adjacent Evidence Outcomes

8 included sources were assigned to this outcome class. Directional coding: null=7, unclear=1. Directness coding: indirect=7, review=1.

Longevity Outcomes

2 included sources were assigned to this outcome class. Directional coding: null=1, unclear=1. Directness coding: indirect=1, review=1.

Frailty Outcomes

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: review=1.

Immune Inflammation Outcomes

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.

Muscle Function Outcomes

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.

Limitations

Verification note: Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The curated corpus lacks randomized controlled trials (RCTs) directly testing senescence-targeting interventions against cancer outcomes, creating a critical gap in establishing causal efficacy. The absence of long-term mortality or recurrence trials in adults with or without cancer limits the ability to translate biomarker associations into clinically actionable endpoints, leaving the boundary conditions for senescence modulation undefined. This limitation is compounded by the inclusion of only one study (Moskalevska 2026) examining longevity outcomes, which reports a 20% survival increase in males but lacks replication in broader populations, further constraining generalizability.

Single-trial dominance for specific outcomes introduces replication risk and undermines the robustness of headline conclusions. These isolated observations cannot support definitive claims about senescence-targeting strategies without corroborating evidence across multiple independent cohorts.

Population specificity severely constrains the external validity of the synthesized evidence, particularly for high-risk or underrepresented groups. The majority of included studies (e.g., Fielding 2022, Blomquist 2026, Shah 2025) focus on general adult or type 2 diabetes populations, with Shah 2025 explicitly limited to post-myocardial infarction patients with diabetes. This narrow enrollment excludes individuals with other comorbid conditions, varying cancer subtypes, or diverse ethnic backgrounds, where senescence-cancer interactions may differ. The absence of trials enrolling non-white populations or those with early-stage cancers further limits the applicability of findings to global demographics, where cancer incidence and senescence biology exhibit substantial heterogeneity. Even studies targeting older adults (e.g., Castillo 2026) rely on frailty frameworks (e.g., Fried et al.) that may not capture the full spectrum of aging-related senescence in oncology.

The scope of measured endpoints in the corpus is narrowly focused on mechanistic and indirect markers, leaving critical clinical outcomes unassessed. While studies such as Sobolewski 2026 and Lin 2021 identify histological and genetic senescence markers in keratinocyte cancers and lung adenocarcinoma, respectively, these do not translate to patient-centered outcomes like progression-free survival, quality of life, or treatment-related toxicity. The reliance on surrogate endpoints (e.g., biomarker shifts in Blomquist 2026 or immune cell phenotypes in Gonnin 2024) introduces uncertainty, as surrogate associations do not guarantee improvements in hard outcomes (Ioannidis 2005). Additionally, the absence of trials measuring functional decline (e.g., gait speed below 0.8 m/s per Studenski 2011) or metabolic endpoints (e.g., HbA1c targets per ADA 2024) in senescence-cancer contexts further underscores the gap between mechanistic hypotheses and clinically meaningful endpoints.

The corpus exhibits a pronounced mechanistic-to-clinical translation gap, where senescence-related claims are supported by preclinical or indirect human data without corresponding clinical validation. For example, Lin 2021 and Fang 2023 link senescence patterns to immunotherapeutic responses and cancer outcomes, respectively, but these associations are not grounded in trials demonstrating that targeting senescence (e.g., via senolytics) improves clinical endpoints. Similarly, Moskalevska 2026 reports healthspan and survival benefits in animal models, yet these findings are not replicated in human RCTs, leaving the clinical feasibility of senescence-targeting strategies uncertain. This disconnect is exacerbated by the inclusion of mechanistic reviews (e.g., Sobolewski 2026) that highlight histological markers without demonstrating their actionability in patient care, further widening the chasm between bench and bedside.

Conclusion

For senescence cancer effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

What This Synthesis Adds

This synthesis maps 13 included sources on Senescence across 5 outcome classes with no cross-study disagreements surfaced. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

Across 13 curated reference papers, the evidence base for Senescence shows a context-dependent profile. Null findings dominate: contextual other, muscle function. The Senescence anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.

Prior reviews in the corpus (Moskalevska 2026) emphasize convergent signals on Senescence. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Evidence domain	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
longevity	0	2	null, unclear	direct interventional hard-endpoint gap
frailty	0	1	null	direct interventional hard-endpoint gap
muscle function	0	1	null	direct interventional hard-endpoint gap
contextual adjacent evidence	0	8	null, unclear	direct interventional hard-endpoint gap
immune and inflammation	0	1	null	direct interventional hard-endpoint gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	longevity: direct interventional hard-endpoint gap	0 direct and 2 indirect sources; direction profile: null, unclear
P2	frailty: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: null
P3	muscle function: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: null
P4	contextual adjacent evidence: direct interventional hard-endpoint gap	0 direct and 8 indirect sources; direction profile: null, unclear
P5	immune and inflammation: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: null

Next-Study Design Recommendation

The next high-yield study for Senescence should target the longevity evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

Load-Bearing Included Studies

• Moskalevska 2026; tier=B1; directness=review; endpoint=longevity; direction=unclear.
• Fielding 2022; tier=B2; directness=indirect; endpoint=muscle function; direction=null; representative statistic=P < 0.001 (off-summary).
• Gonnin 2024; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.0001 (off-summary).
• Sun 2024; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null.
• Liu 2025; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.01 (off-summary).
• Blomquist 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P = 0.005 (off-summary).
• Shah 2025; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear.
• Newell 2026; tier=B2; directness=indirect; endpoint=immune inflammation; direction=null.
• Fang 2023; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P = 0.039 (off-summary).
• Castillo 2026; tier=B2; directness=review; endpoint=frailty; direction=null.

Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

• Targeting the senescence-associated immune checkpoint GD3 ganglioside extends healthspan and blunt age-related diseases with sex-specific benefits: outcome=longevity; directness=review; tier=B1; direction=unclear; claims=1.
• Associations between biomarkers of cellular senescence and physical function in humans: observations from the lifestyle interventions for elders (LIFE) study: outcome=muscle function; directness=indirect; tier=B2; direction=null; claims=47.
• CD57 + EMRA CD8 + T cells in cancer patients over 70: associations with prior chemotherapy and response to anti-PD-1/PD-L1 therapy: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=47.
• Clinical outcomes of autologous adipose-derived mesenchymal stem cell combined with high tibial osteotomy for knee osteoarthritis are correlated with stem cell stemness and senescence: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=43.
• A bibliometric and visual analysis of the impact of senescence on tumor immunotherapy: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=21.
• Exploratory Effects of a Novel Nutraceutical on Senescence-Related Protein Biomarkers in Healthy Adults: A Pilot Proteomics Study: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=17.
• The cardio‐renal‐metabolic role of the nod‐like receptor protein‐3 and senescence‐associated secretory phenotype in early sodium/glucose cotransporter‐2 inhibitor therapy in people with diabetes who have had a myocardial infarction: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=12.
• Attenuation of Immune Senescence Markers After Intensive Cancer Therapy Through Resistance Training: A Pilot Study: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=10.
• Using proteomics and metabolomics to identify therapeutic targets for senescence mediated cancer: genetic complementarity method: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=9.
• Exercise, Cellular Senescence, and Cancer: Novel Perspectives on Functional Aging Through Block Strength Training in Older Adults—A Narrative Review: outcome=frailty; directness=review; tier=B2; direction=null; claims=5.
• Histological and Genetic Markers of Cellular Senescence in Keratinocyte Cancers and Actinic Keratosis: A Systematic Review: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=4.
• Identification and validation of cellular senescence patterns to predict clinical outcomes and immunotherapeutic responses in lung adenocarcinoma: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=3.
• Non-coding RNAs participate in interactions between senescence and gastrointestinal cancers: outcome=longevity; directness=indirect; tier=B2; direction=null; claims=1.

Classification Criteria

• Outcome class is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
• Directness is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
• Directional signal is counted within the assigned outcome class only. A no extracted directional signal cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
• Evidence tier follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

Load-Bearing Tensions

• No load-bearing cross-study disagreements were detected.

Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Liu 2025b, Anisimov 2008.

Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Cruz-Jentoft 2019, Owen 2000.

References

• Gonnin 2024. CD57 + EMRA CD8 + T cells in cancer patients over 70: associations with prior chemotherapy and response to anti-PD-1/PD-L1 therapy. Immunity & Ageing : I & A, 2024. DOI: 10.1186/s12979-024-00487-4. PMID: 39731117.
• Fielding 2022. Associations between biomarkers of cellular senescence and physical function in humans: observations from the lifestyle interventions for elders (LIFE) study. GeroScience, 2022. DOI: 10.1007/s11357-022-00685-2. PMID: 36367600.
• Sun 2024. Clinical outcomes of autologous adipose-derived mesenchymal stem cell combined with high tibial osteotomy for knee osteoarthritis are correlated with stem cell stemness and senescence. Journal of Translational Medicine, 2024. DOI: 10.1186/s12967-024-05814-3. PMID: 39558365.
• Liu 2025. A bibliometric and visual analysis of the impact of senescence on tumor immunotherapy. Frontiers in Immunology, 2025. DOI: 10.3389/fimmu.2025.1566227. PMID: 40292294.
• Blomquist 2026. Exploratory Effects of a Novel Nutraceutical on Senescence-Related Protein Biomarkers in Healthy Adults: A Pilot Proteomics Study. International Journal of Molecular Sciences, 2026. DOI: 10.3390/ijms27104406. PMID: 42196384.
• Shah 2025. The cardio‐renal‐metabolic role of the nod‐like receptor protein‐3 and senescence‐associated secretory phenotype in early sodium/glucose cotransporter‐2 inhibitor therapy in people with diabetes who have had a myocardial infarction. Diabetic Medicine, 2025. DOI: 10.1111/dme.70059. PMID: 40281683.
• Newell 2026. Attenuation of Immune Senescence Markers After Intensive Cancer Therapy Through Resistance Training: A Pilot Study. Cancers, 2026. DOI: 10.3390/cancers18111710. PMID: 42279294.
• Fang 2023. Using proteomics and metabolomics to identify therapeutic targets for senescence mediated cancer: genetic complementarity method. Frontiers in Endocrinology, 2023. DOI: 10.3389/fendo.2023.1255889. PMID: 37745724.
• Castillo 2026. Exercise, Cellular Senescence, and Cancer: Novel Perspectives on Functional Aging Through Block Strength Training in Older Adults—A Narrative Review. Biomedicines, 2026. DOI: 10.3390/biomedicines14040875. PMID: 42072416.
• Sobolewski 2026. Histological and Genetic Markers of Cellular Senescence in Keratinocyte Cancers and Actinic Keratosis: A Systematic Review. International Journal of Molecular Sciences, 2026. DOI: 10.3390/ijms27031520. PMID: 41683940.
• Lin 2021. Identification and validation of cellular senescence patterns to predict clinical outcomes and immunotherapeutic responses in lung adenocarcinoma. Cancer Cell International, 2021. DOI: 10.1186/s12935-021-02358-0. PMID: 34872577.
• Moskalevska 2026. Targeting the senescence-associated immune checkpoint GD3 ganglioside extends healthspan and blunt age-related diseases with sex-specific benefits. bioRxiv preprint, 2026. DOI: 10.64898/2026.01.06.697856.
• Liu 2025b. Non-coding RNAs participate in interactions between senescence and gastrointestinal cancers. Frontiers in Genetics, 2025. DOI: 10.3389/fgene.2024.1461404. PMID: 39831201.

Background References

Canonical reference values and methodological references cited in prose. Each entry's citation_token appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).

• Studenski 2011. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50-58. DOI: 10.1001/jama.2010.1923. PMID: 21205966.
• ADA 2024. American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2024;47(Suppl 1). DOI: 10.2337/dc24-S006.
• Cruz-Jentoft 2019. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31. DOI: 10.1093/ageing/afy169. PMID: 30312372.
• Owen 2000. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000;348 Pt 3:607-614. PMID: 10839993.
• Anisimov 2008. Anisimov VN, Berstein LM, Egormin PA, et al. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle. 2008;7(17):2769-2773. PMID: 18728386.
• Ioannidis 2005. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124. (methodological reference) DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.